Role of the insulin-like growth factor family in cancer development and progression

Journal of the National Cancer Institute

Volumn 92, Issue 18, 2000, Pages 1472-1489

  Yu, Herbert ^a   Rohan, Thomas ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN RECEPTOR; VIRUS PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; COLON CANCER; DIET; ENZYME REGULATION; GENE LOCATION; HIGH ENERGY PHOSPHATE; HUMAN; LIFESTYLE; LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN STRUCTURE; RECTUM CANCER; REVIEW;

EID: 0034692430     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.18.1472     Document Type: Review

References (315)

1. Increased cell division as a cause of human cancer
2. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer
3. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
4. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control study
5. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
6. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation
7. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations
8. Insulin-like growth factors and their binding proteins
9. Insulinlike growth factor-binding proteins
10. The insulin-like growth factor family of ligands, receptors, and binding proteins
11. Insulin-like growth factors and their binding proteins: Biological actions
12. Molecular and cellular aspects of the insulin-like growth factor I receptor
13. Growth, differentiation, and survival: Multiple physiological functions for insulin-like growth factors
14. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
15. Structure and function of the insulin-like growth factor I receptor
16. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene
17. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics
18. Insulin-like growth factor binding proteins and their role in controlling IGF actions
19. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action
20. Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor
21. Sequence of cDNA encoding human insulin-like growth factor I precursor
22. A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells
23. Transcriptional and post-transcriptional regulation of the human IGF-II gene expression
24. Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein
25. Identification of multiple transcription start sites in the human insulin-like growth factor-I gene
26. Tissue-specific transcription start site usage in the leader exons of the rat insulin-like growth factor-I gene: Evidence for differential regulation in the developing kidney
27. Expression of insulin-like growth factor I (IGF-I) mRNA variants in rat bone
28. Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: Developmental relationship of the four promoters
29. Essential promoter elements are located within the 5' untranslated region of human insulin-like growth factor-I exon I
30. Endometrial transcripts of human insulin-like growth factors arise by differential promoter usage
31. Differential regulation of transcription initiation from insulin-like growth factor-I (IGF-I) leader exons and of tissue IGF-I expression in response to changed growth hormone and nutritional status in sheep
32. Effect of fasting on insulin-like growth factor (IGF)-IA and IGF-IB messenger ribonucleic acids and prehormones in rat liver
33. Regulation of insulin-like growth factor II P3 promoter by p53: A potential mechanism for tumorigenesis
34. Expression of insulin-like growth factor II transcripts in Wilms' tumour
35. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas
36. Insulin-like growth factor gene expression in human smooth muscle tumors
37. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells
38. Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma. An in situ hybridization and immunohisto-chemical study
39. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF-II-mediated autocrine loop
40. Parental genomic imprinting of the human IGF2 gene
41. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction
42. Imprinting of the mouse Igf2r gene depends on an intronic CpG island
43. The role of histone acetylation in the allelic expression of the imprinted human insulin-like growth factor II gene
44. Promoter-specific imprinting of the human insulin-like growth factor-II gene
45. Promoter-specific insulin-like growth factor 2 gene imprinting in human fetal liver and hepatoblastoma
46. Loss of imprinting of the IGF2 gene in a Wilms' tumor in an adult
47. Loss of im-printing in normal tissue of colorectal cancer patients with microsatellite instability
48. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues
49. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors
50. Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures
51. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro
52. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
53. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cis-platinum
54. IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors
55. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product
56. Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells
57. Expression of IGF ligand and receptor genes during preimplantation mammalian development
58. Expression of mRNA for the insulin-like growth factors and their receptors in human preimplantation embryos
59. Expression and characterization of a functional human insulin-like growth factor I receptor
60. Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors
61. Insulin-like growth factor II receptor as a multifunctional binding protein
62. The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells
63. Type-2 IGF receptor: A multi-ligand binding protein
64. Opposite regulation of IGF-I and IGF-I receptor mRNA and concomitant changes of GH receptor and IGF-II/M6P receptor mRNA in human IM-9 lymphoblasts
65. Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor
66. Fibroblast growth factor inhibits insulin-like growth II (IGF-II) gene expression and increases IGF-I receptor abundance in BC3H-1 muscle cells
67. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene
68. Increased expression of the insulin-like growth factor-1 receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product
69. Dysregulation of the type 1 IGF receptor as a paradigm in tumor progression
70. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene
71. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal
72. Nutritional regulation of the insulin-like growth factors
73. Tissue-specific effects of chronic dietary protein restriction and gastrostomy on the insulin-like growth factor-I pathway in the liver and colon of adult rats
74. Insulin-like growth factor-I and II receptor expression in rat colon mucosa are affected by dietary lipid intake
75. Coordinate expression of insulin-like growth factor II (IGF-II) and IGF-II/mannose-6-phosphate receptor mRNA and stable expression of IGF-I receptor mRNA during differentiation of human colon carcinoma cells (Caco-2)
76. Insulin-like growth factors I and II are autocrine factors in stimulating proteoglycan synthesis, a marker of differentiated chondrocytes, acting through their respective receptors on a clonal human chondrosarcoma-derived chondrocyte cell line, HCS-2/8
77. Different regulation of signaling pathways for insulin and insulin-like growth factor I
78. The insulin-like growth factor I receptor: A key to tumor growth?
79. Type II insulin-like growth factor receptor is present in rat serum
80. Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain
81. Soluble insulin-like growth factor II/mannose 6-phosphate receptor carries multiple high molecular weight forms of insulin-like growth factor II in fetal bovine serum
82. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanism
83. Developmental regulation of the soluble form of insulin-like growth factor-II/mannose 6-phosphate receptor in human serum and amniotic fluid
84. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: Measurement by enzyme-linked immunosorbent assay
85. IGF-independent regulation of breast cancer growth by IGF binding proteins
86. Insulin-like growth factor binding proteins: A proposed superfamily
87. Contiguous localization of the genes encoding human insulin-like growth factor binding proteins 1 (IGBP1) and 3 (IGBP3) on chromosome 7
88. Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5
89. The human insulin-like growth factor binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer
90. Characterization and chromosomal localization of the human insulin-like growth factor-binding protein 6 gene
91. Insulin-like growth factor binding protein-1: Recent findings and new directions
92. Evidence for insulin-like growth factor (IGF)-independent transcriptional regulation of IGF binding protein-3 by growth hormone in SKHEP-1 human hepatocarcinoma cells
93. Cortisol enhances the transcription of insulin-like growth factor-binding protein-6 in cultured osteoblasts
94. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation
95. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3
96. Thyroid hormone and retinoic acid induce the synthesis of insulin-like growth factor-binding protein-4 in mouse osteoblastic cells
97. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: Stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol
98. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action
99. Retinoic acid regulates insulin-like growth factor-binding protein expression in human osteoblast cells
100. Growth factor regulation of insulin-like growth factor binding protein-6 expression in osteoblasts
101. Retinoic acid stimulates IGF binding protein (IGFBP)-6 and depresses IGFBP-2 and IGFBP-4 in SK-N-SH human neuroblastoma cells
102. Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein-3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes
103. Proteolysis of insulin-like growth factors (IGF) and IGF binding proteins by cathepsin D
104. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo effect on affinity for IGF-I
105. Phosphorylation of insulin-like growth factor binding proteins
106. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells
107. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
108. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: Kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule
109. 7S nerve growth factor is an insulin-like growth factor-binding protein protease
110. HaCaT human keratinocytes express IGF-II, IGFBP-6, and an acid-activated protease with activity against IGFBP-6
111. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
112. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease
113. Proteolysis of IGFBPs by cathepsin D in vitro and in cathepsin D-deficient mice
114. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures
115. Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metalloproteinase in human pregnancy serum
116. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells
117. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells
118. Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin
119. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A
120. Human pregnancy serumcontains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3
121. The role of IGFBP-3 in the regulation of IGFBP-4 proteolysis
122. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity
123. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
124. Insulin-like growth factor binding protein-3 proteolysis in children with insulin-dependent diabetes mellitus: A possible role for insulin in the regulation of IGFBP-3 protease activity
125. Postoperative induction of insulin-like growth factor binding protein-3 proteolyric activity: Relation to insulin and insulin sensitivity
126. No effect of growth, hormone on serum insulin-like growth factor binding protein-3 proteolysis
127. Regulation of insulin-like growth factor-binding protein-4 protease activity by estrogen and parathyroid hormone in SaOS-2 cells: Implications for the pathogenesis of postmenopausal osteoporosis
128. Insulin-like growth factors and cancer
129. Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium
130. Insulin-like growth factors and cancer
131. Relaxation of insulin-like growth factor-II gene imprinting in human gynecologic tumors
132. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: Role of IGF-II
133. In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute my-elogenous leukemia blasts
134. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice
135. Mammary cancer in transgenic mice expressing insulin-like growth factor-II (IGF-II)
136. Involvement of IGF-II in human cancer
137. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level
138. Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma
139. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocar-cinomas of different metastasizing ability
140. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1
141. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor 1 receptor antisense ribonucleic acid
142. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor
143. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype
144. Expression of insulin-like growth factor-1 receptor in human colorectal cancer
145. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer
146. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling
147. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism
148. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations
149. Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cell
150. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells
151. Identification of insulin-like growth factor binding proteins in breast cancer cells
152. Insulin-like growth factor binding proteins in human breast cancer tissue
153. Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells
154. Insulin-like growth factor binding protein production in human follicular thyroid carcinoma cells
155. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells
156. Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization
157. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors
158. Insulin-like growth factor binding protein-1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells
159. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells
160. Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF-I-induced stimulation of osteoblasts: Control of IGF signalling to bone cells by IGFBP-3-specific proteolysis?
161. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast cancer carcinoma cell line
162. Secretion and biological actions of insulin-like growth factor binding proteins in two human tumor-derived cell lines in vitro
163. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner
164. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53- and IGF-independent mechanism
165. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid
166. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
167. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I
168. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone
169. Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cells
170. Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: Evidence for stromal epithelial interactions
171. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes
172. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: Correlation with estrogen receptor status
173. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status
174. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditional media
175. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
176. A role of insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780
177. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen
178. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
179. Estrogen induces insulin-like growth factor-I expression in the rat uterus
180. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780
181. Impaired estrogen action in the uterus of insulin-like growth factor binding protein-1 transgenic mice
182. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins
183. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol
184. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
185. Effects of insulin-like growth factors I and II on oestrone sulphatase activity in human breast cancer cell lines
186. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells
187. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells
188. Epidermal growth factor suppresses insulin-like growth factor binding protein 3 levels in human papilloma-virus type 16-immortalized cervical epithelial cells and thereby potentiates the effects of insulin-like growth factor 1
189. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines
190. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus X gene product
191. The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4
192. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma
193. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells
194. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells
195. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25 (OH) 2D3 and its analog EB1089
196. Induction of the growth inhibitor IGF-binding protein 3 by p53
197. p53 Regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells
198. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer
199. p53 Regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: Interaction between p53 and Sp1
200. Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells
201. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site
202. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor
203. Suppression of mammary-derived growth inhibitor gene expression by growth hormone and insulin-like growth factor I
204. PTEN gene transfer in human malignant glioma: Sensitization to irradiation and CD95L-induced apoptosis
205. Influence of dietary fat, caloric restriction, and voluntary exercise on N-nitrosomethylurea-induced mammary tumorigenesis in rats
206. Effect of caloric restriction on age-associated cancers
207. Caloric restriction and experimental carcinogenesis
208. Caloric restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice
209. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression
210. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice
211. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum
212. Acid-labile subunit of human insulin-like growth factor-binding protein complex: Measurement, molecular, and clinical evaluation
213. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency
214. Influence of physical activity on insulin-like growth factor-I in healthy younger and older men
215. Somatomedin-C, physical fitness, and bone density
216. Age-related changes in serum insulin-like growth factor-binding proteins in women
217. Effect of obesity on plasma insulin-like growth factor-I in cancer patients
218. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults
219. Low concentrations of insulin-like growth factor-I in abdominal obesity
220. Serum insulin-like growth factor I in a random population sample of men and women: Relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin
221. Relations of endogenous anabolic hormones and physical activity to bone mineral density and lean body mass in elderly men
222. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in ultrasensitive chemiluminescence assay
223. Epidemiology of insulin-like growth factor-1 in elderly men and women. The Rancho Bernardo Study
224. Aging, physical activity, insulin-like growth factor I, and body composition in Guatemalan women
225. Serum free IGF-I, total IGF-I, IGFBP-I and IGFBP-3 levels in an elderly population: Relation to age and sex steroid levels
226. Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation
227. Reduction of plasma immunoreactive somatomedin C during fasting in humans
228. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: Effects of anabolism, lipolysis, and body composition
229. Hormonal response to overfeeding
230. Serum insulin-like growth factor I in healthy older men in relation to physical activity
231. Testosterone, growth hormone and IGF-I responses to acute and chronic resistive exercise in men aged 55-70 years
232. Effect of regular physical training on age-associated alteration of body composition in men
233. Plasma insulin-like growth factor-I and high affinity growth hormone-binding protein levels increase after two weeks of strenuous physical training
234. Responses of total and free insulin-like growth factor-I and insulin-like growth factor binding protein-3 after resistance exercise and training in elderly subjects
235. Physical fitness, endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females
236. Increased physical activity and the growth hormone-IGF-I axis in adolescent males
237. Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer
238. Nutritional regulation of IGF-I and IGFBPs
239. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index
240. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation
241. Population-based reference values for IGF-I and IGF-binding protein-1: Relations with metabolic and anthropometric variables
242. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation
243. The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: Hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency
244. Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: Implications for bone loss with aging
245. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor binding proteins in postmenopausal women
246. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults
247. Regulation by fasting of rat insulin-like growth factor I and its receptor. Effects on gene expression and binding
248. Effect of fasting on insulin-like growth factor-I (IGF-I) and growth hormone receptor mRNA levels and IGF-I gene transcription in rat liver
249. Effect of dietary protein deprivation on insulin-like growth factor (IGF)-I and -II, IGF binding protein-2, and serum albumin gene expression in rat
250. Reduced serum concentrations of insulin-like growth factor-I (IGF-I) in protein-restricted growing rats are accompartied by reduced IGF-I mRNA levels in liver and skeletal muscle
251. Effect of dietary proteins on insulin-like growth factor-1 (IGF-1) messenger ribonucleic acid content in rat liver
252. Nutritional regulation of hormones and growth factors that control mammalian growth
253. Effect of exercise on cytokines and growth mediators in prepubertal children
254. Insulin-like growth factors I and II in evaluation of growth retardation
255. Physiologic and clinical relevance of the insulin-like growth factor binding proteins
256. Evaluation of acromegaly by radio-immunoassay of somatomedin-C
257. Insulin-like growth factors (IGF)-I and -II and IGF binding protein-1, -2, and -3 in patients with acromegaly before and after adenomectomy
258. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
259. Normal growth and development in the absence of hepatic insulin-like growth factor I
260. Effects of alcohol and liver cirrhosis on the GH-IGF-I axis
261. Ethanol enhances the stimulatory effects of insulin and insulin-like growth factor-1 on DNA synthesis in NIH 3T3 fibro-blasts
262. Effects of ethanol on the intraovarian insulin-like growth factor-1 system in the prepubertal rat
263. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3
264. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer
265. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human cancer
266. Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin
267. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: Mutual relationship and possible correlations with patients' hormonal status
268. Serum IGF-binding protein-6 and prostate specific antigen in breast cancer
269. Serum concentrations of insulin-like growth factor 1 in colonic neoplasia
270. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer
271. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: Comparison of endometrial cancer patients with healthy controls
272. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer
273. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia
274. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression Of breast cancer, and predict the risk of recurrence and the probability of survival in African-Amercian and Hispanic women
275. Insulin-like growth factor-I expression in normal and diseased endometrium
276. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
277. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection
278. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
279. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen
280. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate
281. Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium
282. Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization
283. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer
284. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor
285. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid
286. Circulating epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) in patients with epithelial ovarian carcinoma
287. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast
288. Insulin and related factors in premenopausal breast cancer risk
289. Insulin-like growth factor-I and breast cancer risk in postmenopausal African-American women
290. Plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal cancer and adenoma in women
291. IGF-I and IGF-II in relation to colorectal cancer
292. Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia
293. Insulin-like growth factor I in relation to prostate cancer and benign prostatic hyperplasia
294. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
295. Insulin-like growth factor-binding protein-1 and prostate cancer
296. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors
297. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer
298. Insulin-like growth factor-1 receptors and insulin-like growth
299. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer
300. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer
301. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors
302. IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma
303. Insulin-like growth factor binding proteins in human breast cancer tissue
304. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status
305. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues
306. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer
307. Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study
308. Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis
309. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features
310. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
311. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
312. Insulin-like growth factor-binding protein-3 and breast cancer survival
313. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
314. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer